David Pearlman is Senior Principal Scientist and Product Manager for the biologics software platform at Schrödinger. He received his Ph.D. at the University of California, Berkeley working with Dr. Sung-Hou Kim, where he received the first degree from that institution to focus on modern computational studies of macromolecules (primarily nucleic acids). He left Berkeley to be a founding employee of Biosym Technologies, later Accelrys. Subsequently, Dr. Pearlman did his post-doctoral work at University of California, San Francisco, with Peter Kollman, where he was primary developer of the widely-used AMBER program and also published a string of seminal papers in the field of free energy perturbation. Leaving UCSF, Dr. Pearlman became an early employee of Vertex Pharmaceuticals, where he continued to work and publish on free energy methods, as well on new approaches to NMR refinement, de novo ligand design and ligand scoring. From Vertex, Dr. Pearlman spent a few years providing direction for computational chemistry at The Stanley Center of the Broad Institute before coming to Schrodinger in 2010, to oversee the design and implementation of the BioLuminate program.

David Pearlman is Senior Principal Scientist and Product Manager for the biologics software platform at Schrödinger. He received his Ph.D. at the University of California, Berkeley working with Dr. Sung-Hou Kim, where he received the first degree from that institution to focus on modern computational studies of macromolecules (primarily nucleic acids). He left Berkeley to be a founding employee of Biosym Technologies (later Accelrys) where he lead the lead the Discover platform—the first commercially marketed macromolecular software package. Subsequently, Dr. Pearlman did post-doctoral work at University of California, San Francisco, with Peter Kollman, where he developed the widely-used AMBER program and also published a string of seminal papers in the field of free energy perturbation. Leaving UCSF, Dr. Pearlman became an early employee of Vertex Pharmaceuticals, where he continued to work and publish on free energy methods, as well on new approaches to NMR refinement, de novo ligand design and ligand scoring. From Vertex, Dr. Pearlman spent a few years providing direction for computational chemistry at The Stanley Center of the Broad Institute before coming to Schrodinger in 2010, to oversee the design and implementation of the biologics software platform (including BioLuminate).